Platelet Function in Patients With Hemophilia A
NCT02093065 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36
Last updated 2020-07-14
Summary
Abnormalities in the gene encoding Factor VIII (FVIII) results in hemophilia A, an X-linked recessive bleeding disorder with a prevalence of 1 in 5000 males. Hemophilia A patients are classified into 3 different categories based on residual FVIII activity compared to normal: mild (6-40%), moderate (1-5%) and severe (\<1%). This categorization correlates to some degree with bleeding phenotype, but does not completely define it. Some patients with hemophilia A bleed less often than others despite identical plasma FVIII levels. The cause(s) of this phenotype heterogeneity in hemophilia A remains largely unknown, despite a number of studies of possible factors.
Activated platelets, in addition to their role in primary hemostasis, play a major role in secondary hemostasis (coagulation) by providing a phospholipid surface to which coagulation factors bind. A role for platelets in the hemorrhagic propensity of hemophilia A has been suggested in the past, but only a small number of studies have been performed with limitations in assays performed and numbers of patients. The purpose of the present study is to determine whether platelet reactivity in severe hemophilia A patients is associated with past bleeding frequency and/or predicts future bleeding frequency.
Conditions
Sponsors & Collaborators
-
Baxter Healthcare Corporation
collaborator INDUSTRY - lead OTHER
Principal Investigators
-
Alan D Michelson, MD · Boston Children's Hospital
Eligibility
- Min Age
- 2 Years
- Max Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-03-31
- Primary Completion
- 2018-06-30
- Completion
- 2020-02-01
Countries
- United States
Study Locations
More Related Trials
-
Hemophilia Inhibitor Previously Untreated Patient Study
NCT01652027 ·Status: COMPLETED
-
Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
NCT01571934 ·Status: COMPLETED
-
Assessment of Quality of Life in Hemophiliac Patients
NCT03159663 ·Status: UNKNOWN
-
Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity
NCT02911233 ·Status: COMPLETED
-
Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients
NCT02540187 ·Status: COMPLETED
-
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
NCT00178607 ·Status: COMPLETED
-
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A
NCT00782470 ·Status: COMPLETED
-
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
NCT02396862 ·Status: COMPLETED
-
Rituximab to Treat Severe Hemophilia A
NCT00331006 ·Status: COMPLETED ·Phase: PHASE2
-
Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B
NCT03287999 ·Status: UNKNOWN
-
Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
NCT00995046 ·Status: TERMINATED ·Phase: NA
-
Genetic Susceptibility to Factor VIII Inhibitors
NCT00344435 ·Status: COMPLETED
-
Epidemiology and Immunology of Hemophilia A Inhibitors
NCT00005518 ·Status: COMPLETED
-
Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A
NCT02280265 ·Status: UNKNOWN ·Phase: NA
-
Prophylaxis Versus on Demand Treatment for Children With Hemophilia A
NCT01810666 ·Status: COMPLETED ·Phase: PHASE4
-
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
NCT05022459 ·Status: RECRUITING
-
Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A
NCT05265767 ·Status: COMPLETED ·Phase: PHASE1
-
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
NCT01626105 ·Status: UNKNOWN
-
Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A
NCT05628558 ·Status: UNKNOWN
-
2-cohort Study of Adult Patients With Severe Hemophilia A in Greece
NCT02319070 ·Status: COMPLETED
-
Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens
NCT00927667 ·Status: COMPLETED ·Phase: PHASE4
-
EVALUATION of the OVERALL HAEMOSTATIC CAPACITY of MIM8 with GLOBAL HAEMOSTASIS ASSAYS and FIBRIN CLOT ULTRASTRUCTURE
NCT06212505 ·Status: COMPLETED
-
Study Evaluating Inhibitor Specificity in Hemophilia A
NCT00151385 ·Status: WITHDRAWN ·Phase: PHASE4
-
Comparison of Pulmonary Function, Exercise Capacity, and Physical Activity Level Between Children With Hemophilia and Healthy Controls
NCT06636565 ·Status: COMPLETED
-
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
NCT03818763 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1